Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sionna TherapeuticsSION +4.40%12 3-Year EBITDA Growth Rate is 2.40% as of Mar. 2026, which is at its 10-year median of 2.40. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,135 Biotechnology companies, Sionna Therapeutics ranks worse than 66.61% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sionna Therapeutics was 2.40% per year. The lowest was 2.40% per year. And the median was 2.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sionna Therapeutics 3-Year EBITDA Growth Rate Related Terms
SION vs HRMY, VRDN, URGN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Sionna Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sionna Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sionna Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sionna Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 2.40% mean?
Sionna Therapeutics (SION) has a 3-Year EBITDA Growth Rate of 2.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sionna Therapeutics and its competitors. This is near median its historical median of 2.40. Over the past decade, Sionna Therapeutics' 3-Year EBITDA Growth Rate has ranged from 2.40 to 2.40. According to the industry distribution chart, Sionna Therapeutics ranks #756 out of 1135 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Sionna Therapeutics' 3-Year EBITDA Growth Rate too high?
Sionna Therapeutics' current 3-Year EBITDA Growth Rate of 2.40% is near median its 10-year median of 2.40. Over the past 10 years, this metric has ranged from a low of 2.40 to a high of 2.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Sionna Therapeutics' value of 2.40% is 83.9% below this industry median. Based on the distribution chart, Sionna Therapeutics ranks #756 out of 1135 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' 3-Year EBITDA Growth Rate compare to HRMY and VRDN?
According to the Biotechnology industry distribution chart, Sionna Therapeutics ranks #756 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Sionna Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Sionna Therapeutics' value of 2.40% is 83.9% below this benchmark. Historically, Sionna Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 2.40 to 2.40 over the past decade. While the company's 10-year median is 2.40 vs. the industry median of 14.90, Sionna Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sionna Therapeutics's current 3-Year EBITDA Growth Rate of 2.40% is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sionna Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sionna Therapeutics's current 3-Year EBITDA Growth Rate is 2.40%, which is near median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current 3-Year EBITDA Growth Rate of 2.40%. The current 3-Year EBITDA Growth Rate is 2.40%, which is near median its 10-year median of 2.40 and 83.9% below the Biotechnology industry median of 14.90. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current 3-Year EBITDA Growth Rate is 2.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score
Get the complete analysis for SION
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SION has been successfully added to your 
